Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee. RESULTS: A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups. CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib (Section 7.6) is an on-target, mechanism-based class effect.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib, a selective COX-2 inhibitor, was withdrawn from the market in 2004 following the VIGOR and APPROVe trials, which revealed a sustained excess of thrombotic cardiovascular events.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal efficacy and short-term human safety data had been reassuring; only long-term cardiovascular outcome trials surfaced the signal.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mechanism is generally ascribed to disruption of the prostacyclin–thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A2 production [77,78].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Items 801–900 of 1,003
KLEIN, T., Eltze, M., Grebe, T., Hatzelmann, A., & Kömhoff, M. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.02.026 · Cited by 45
“The observation that cardiovascular side effects are increased (compared to placebo) not only with the methylsulfon group containing drug rofecoxib [3] but also with the arylsulfon group containing drug celecoxib [4] argues for a class-effect.”
BackgroundPhytochemicals and colorectal cancer prevention—myth or reality?
Ricciardiello, L., Bazzoli, F., & Fogliano, V. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.149 · Cited by 40
Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC
Moore, N. D., Salvo, F., Duong, M., Blin, P., & Pariente, A. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.846324 · Cited by 39
“On balance the preferred hypothesis, supported by relatively late increase in risk in the APPROVe study [2], is the interaction with blood pressure, that is, increased risk associated with long-term use.”
BackgroundCyclooxygenase-2 Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Cardiovascular Risk
Vardeny, O., & Solomon, S. D. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.06.004 · Cited by 41
Colucci, J. T., Boyd, M. J., Berthelette, C., Chiasson, J.-F., Wang, Z., Ducharme, Y., Friesen, R. W., Wrona, M. D., Lévesque, J.-F., Denis, D., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.065 · Cited by 39
Sánchez, A., Contreras, C., Martínez, M. P., Villalba, N., Benedito, S., García‐Sacristán, A., Salaíces, M., Hernández, M., & Prieto, D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.09.022 · Cited by 39
Drug-Induced Cardiovascular Disorders
Murphy, C. A., & Dargie, H. J. (2007) · Drug Safety · doi:10.2165/00002018-200730090-00005 · Cited by 40
Roles of Lipid Mediators in Kidney Injury
Hao, C., & Breyer, M. D. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.02.008 · Cited by 46
Cardiovascular Biology of Microsomal Prostaglandin E Synthase-1
Wang, M., & FitzGerald, G. A. (2010) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2011.04.002 · Cited by 39
“2006),consistent with the predisposition to myocardial infarction and stroke observed in placebo controlled trials of pdNSAIDs selective for inhibition of COX-2(Bresalier et al. 2005; Grosser et al. 2006; Solomon et al. 2005).”
BackgroundPPAR‐δ in Vascular Pathophysiology
Wang, N. (2008) · PPAR Research · doi:10.1155/2008/164163 · Cited by 40
“As COX-2 inhibitors suppressed PPAR-δ activity and induced TF expression, these results may help explaining the prothrombotic adverse effects of the cox-2 inhibitors rofecoxib and valdecoxib [41].”
BackgroundFerner, R. E. (2005) · BMJ · doi:10.1136/bmj.330.7496.855 · Cited by 39
Dysregulation of cellular membrane homeostasis as a crucial modulator of cancer risk
Erazo‐Oliveras, A., Muñoz‐Vega, M., Salinas, M. L., Wang, X., & Chapkin, R. S. (2022) · FEBS Journal · doi:10.1111/febs.16665 · Cited by 42
Chun, K., Kim, E., Kim, D., Song, N., Kim, W., Na, H., & Surh, Y. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116259 · Cited by 42
Alacqua, M., Trifirò, G., Cavagna, L., Caporali, R. F., Montecucco, C., Moretti, S., Tari, D. U., Galdo, M., Caputi, A. P., & Arcoraci, V. (2008) · Arthritis Care & Research · doi:10.1002/art.23526 · Cited by 38
Wahab, I. A., Pratt, N. L., Ellett, L. M. K., & Roughead, E. E. (2013) · Drug Safety · doi:10.1007/s40264-013-0124-9 · Cited by 39
Kasciuškevičiūtė, S., Gumbrevičius, G., Vendzelytė, A., Ščiupokas, A., Petrikonis, K., & Kaduševičius, E. (2018) · Medicina · doi:10.3390/medicina54020030 · Cited by 38
Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis
Feng, X., Tian, M., Zhang, W., & Mei, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190798 · Cited by 38
Yoshioka, K., Kisukeda, T., Zuinen, R., Yasuda, Y., & Miyamoto, K. (2018) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-018-2077-8 · Cited by 41
“Meanwhile, oral NSAIDs including diclofenac sodium (DF-Na) were also reported to have the same concerns as COX-2 inhibitors [4, 5].”
BackgroundRörsch, F., Wobst, I., Zettl, H., Schubert‐Zsilavecz, M., Grösch, S., Geißlinger, G., Schneider, G., & Proschak, E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9012505 · Cited by 38
Narsinghani, T., & Sharma, R. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12292 · Cited by 38
Howell, A., Sims, A. H., Ong, K. R., Harvie, M., Evans, D. G., & Clarke, R. B. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0361 · Cited by 40
JIMÉNEZ, P., Piazuelo, E., Cebrián, C., Ortego, J., Strunk, M. H. P., García-González, M. A., Santander, S., Alcedo, J., & Lanas, Á. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04172.x · Cited by 38
Odom, D. M., Mladsi, D. M., Saag, K. G., Sherif, B. N., Miles, L., Ronquest, N. A., & Wang, J. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.04.012 · Cited by 38
“particular, rofecoxib, a COX-2–selective inhibitor, was removed from the market in late 2004 when a clinical study demonstrated that the drug was associated with increased rates of CV events in patients with colorectal polyps.(3) Subsequently, efforts focused on understanding whether the risks observed with rofecoxib…”
Ushiyama, S., Yamada, T., Murakami, Y., Kumakura, S., Inoue, S., Suzuki, K., Nakao, A., Kawara, A., & Kimura, T. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.08.034 · Cited by 38
Cross, J. T., Poole, E. M., & Ulrich, C. M. (2008) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500487 · Cited by 38
Gosset, M., Pigenet, A., Salvat, C., Berenbaum, F., & Jacques, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903315 · Cited by 38
Burnier, M. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.3.491 · Cited by 39
“The first conclusive data came from the APPROVe study, a randomised, placebo-controlled, double-blind study which was performed to investigate the effects of three years of treatment with rofecoxib on the recurrence of adenomatous polyps of the large bowel in patients with a history of colorectal adenomas [46].”
BackgroundMethodShah, R. R. (2007) · Drug Safety · doi:10.2165/00002018-200730120-00003 · Cited by 41
Rofecoxib in the Acute Treatment of Migraine: A Randomized Controlled Clinical Trial
Saper, J., Dahlof, C., So, Y., Tfelt‐Hansen, P., Malbecq, W., Loeys, T., Barraclough, E., Klipfel, M., Lines, C., Visser, H., et al. (2006) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2006.00334.x · Cited by 38
Self-citationEmerging drugs in endometriosis
Mihalyi, A., Simsa, P., Mutinda, K. C., Meuleman, C., Mwenda, J. M., & D’Hooghe, T. M. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.503 · Cited by 39
“Furthermore, long-term use of COX-2 inhibitors has been associated with increased risk of cardiovascular side effects [135], which can be a serious limiting factor.”
BackgroundCardiovascular disease in patients with spondyloarthropathies
Vinsonneau, U., Brondex, A., Mansourati, J., Saraux, A., Cornily, J. C., Arlès, F., Godon, P., & Quiniou, G. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.04.011 · Cited by 38
Chen, L., & Ashcroft, D. M. (2006) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2006.00774.x · Cited by 38
Jankowski, J. A., & Hawk, E. T. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0412 · Cited by 39
Evaluating Drug Effects in the Post-Vioxx World
Avorn, J. (2006) · Circulation · doi:10.1161/circulationaha.106.625749 · Cited by 38
Luyten, F. P., Geusens, P., Malaise, M., Clerck, L. S. D., Westhovens, R., Raeman, F., Mijnsbrugge, D. V., Mathy, L., Hauzeur, J., Keyser, F. D., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.052308 · Cited by 37
Pain Management in Plastic Surgery
Schoenbrunner, A. R., & Janis, J. E. (2020) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2019.12.001 · Cited by 37
Chemoprevention of familial adenomatous polyposis
Lynch, P. M. (2016) · Familial Cancer · doi:10.1007/s10689-016-9901-9 · Cited by 37
“nomas is now largely of historic interest, due to an unsatisfactory cardiovascular safety signal observed in sporadic adenoma trials [13, 14].”
BackgroundProstaglandin E2synthase inhibition as a therapeutic target
Iyer, J. P., Srivastava, P. K., Dev, R., Dastidar, S. G., & Ray, A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903018932 · Cited by 39
“Selective inhibition of COX-2 was found to alter the ratio of these two mediators with a bias towards TxA2 [9-11], leading to high incidence of vascular events, sudden myocardial infarction (MI) and thrombosis in long-term users of coxibs [12,13].”
BackgroundSugita, R., Kuwabara, H., Kubota, K., Sugimoto, K., Kiho, T., Tengeiji, A., Kawakami, K., & Shimada, K. (2016) · Mediators of Inflammation · doi:10.1155/2016/9847840 · Cited by 36
COX-2 Active Agents in the Chemoprevention of Colorectal Cancer
Kraus, S. R., Naumov, I., & Arber, N. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-30331-9_5 · Cited by 36
“In 1999 and 2000 three international, multicenter, prospective, randomized, placebo-controlled trials in the secondary prevention of CRC were launched (Baron et al. 2006; Bertagnolli et al. 2006, 2009; Bresalier et al. 2005).”
BackgroundRisk of acute myocardial infarction with real‐world NSAIDs depends on dose and timing of exposure
Bally, M., Beauchamp, M., Abrahamowicz, M., Nadeau, L., & Brophy, J. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4358 · Cited by 37
COX-2 Signaling in the Tumor Microenvironment
Zhang, Y., Tighe, S. P., & Zhu, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50224-9_6 · Cited by 39
Fibromyalgia Is Associated With Coronary Heart Disease: A Population-Based Cohort Study
Tsai, P., Fan, Y., & Huang, C. (2014) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0000000000000190 · Cited by 42
Policy alternatives for treatments for rare diseases
Panju, A. H., & Bell, C. M. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.081429 · Cited by 42
Republished: Drug-induced gastrointestinal disorders
Philpott, H., Nandurkar, S., Lubel, J. S., & Gibson, P. R. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-100316rep · Cited by 42
Tam, H., Yeo, K., Leong, P., Chen, C.-H., Li, Y., Ma, C.-M., Wang, Y., Chiou, J., & Wei, J. C. (2016) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12986 · Cited by 36
Ahn, S. Y., Kim, N. H., Lee, K., Cha, Y. H., Yang, J. H., Cha, S. Y., Cho, E. S., Lee, Y., Cha, J. S., Cho, H. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16252 · Cited by 37
Kapoor, M., Kojima, F., Qian, M., Yang, L., & Crofford, L. J. (2006) · The FASEB Journal · doi:10.1096/fj.06-6366fje · Cited by 36
Cyclooxygenase-2 Inhibitors Enhance Shear Stress-Induced Platelet Aggregation
Borgdorff, P., Tangelder, G. J., & Paulus, W. J. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.053 · Cited by 36
Influence on platelet aggregation of i.v. parecoxib and acetaminophen in healthy volunteers
Munsterhjelm, E., Niemi, T., Ylikorkala, O., Neuvonen, P. J., & Rosenberg, P. H. (2006) · British Journal of Anaesthesia · doi:10.1093/bja/ael108 · Cited by 36
Tegeder, I., & Geißlinger, G. (2006) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-006-0044-7 · Cited by 40
“Kaplan Meier curves started to diverge after 18 months of treatment (Bresalier et al. 2005).”
BackgroundInfluentialCurrent state of therapy for pain and inflammation.
Abramson, S. B., & Weaver, A. L. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1792 · Cited by 36
Acetaminophen Use and Risk of Myocardial Infarction and Stroke in a Hypertensive Cohort
Fulton, R. L., Walters, M. R., Morton, R., Touyz, R. M., Dominiczak, A. F., Morrison, D. S., Padmanabhan, S., Meredith, P. A., McInnes, G. T., & Dawson, J. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04945 · Cited by 35
“safety of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective inhibitors of cyclo-oxygenase (COX)-2.(2,3) However, recent data suggest that acetaminophen also inhibits COX-2(4) via a peroxidase site on prostaglandin H2 synthase(5) and may have a central action on a further COX variant.”
BackgroundCyclooxygenase-1 and -2: Molecular Targets for Cervical Neoplasia
Kim, H. S., Kim, T., Kim, M.-K., Suh, D. H., Chung, H. H., & Song, Y. S. (2013) · Journal of Cancer Prevention · doi:10.15430/jcp.2013.18.2.123 · Cited by 38
“However, rofecoxib was withdrawn from the market on September 2004 because of the serious adverse event found in Adenomatous Polyp Prevention on VioxxR (APPROVe) trial, demonstrating that the group assigned to rofecoxib had a fourfold increased risk of serious thromboembolic events including acute myocardial infarctio…”
BackgroundZhou, Y., Hu, Z., Zeng, F. J., & Han, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151939 · Cited by 35
Developing Modern Pain Therapies
Manion, J., Waller, M. A., Clark, T., Massingham, J. N., & Neely, G. G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01370 · Cited by 39
Salla, M., Pandya, V., Bhullar, K. S., Kerek, E. M., Wong, Y. F., Losch, R., Ou, J., Aldawsari, F. S., Velázquez‐Martínez, C. A., Thiesen, A., et al. (2020) · Molecules · doi:10.3390/molecules25173849 · Cited by 36
“Other NSAIDs such as rofecoxib showed effective cancer prevention properties but toxicity associated with the daily doses led to a drawback in their use [15].”
BackgroundWho Needs Gastroprotection in 2020?
Kanno, T., & Moayyedi, P. (2020) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-020-00316-9 · Cited by 38
Stoppoloni, D., Cardillo, I., Verdina, A., Vincenzi, B., Menegozzo, S., Santini, M., Sacchi, A., Baldi, A., & Galati, R. (2008) · Cancer · doi:10.1002/cncr.23904 · Cited by 35
Renard, J.-F., Lecomte, F., Hubert, P., de Leval, X., & Pirotte, B. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.12.033 · Cited by 35
Spisni, E., Valerii, M. C., Fazio, L. D., Cavazza, E., Borsetti, F., Sgromo, A., Candela, M., Centanni, M., Rizzello, F., & Strillacci, A. (2014) · Molecular Therapy · doi:10.1038/mt.2014.222 · Cited by 35
Hennekens, C. H., & Borzak, S. L. (2008) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248407312990 · Cited by 36
“The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial was designed to test whether 25 mg of rofecoxib daily compared with placebo decreased the recurrence of cancerous colon polyps.(41) In a subgroup analysis, during the first 18 months, there was no apparent difference in the rate of confirmed thrombotic events,…”
MethodChan, M. W. Y., Wong, C., Cheng, A. S. L., Chan, V., Chan, K., To, K. F., Chan, F. K. L., Sung, J. J. �., & Leung, W. K. (2007) · Oncology Reports · doi:10.3892/or.18.6.1557 · Cited by 35
Seo, T., Tatsuguchi, A., Shinji, S., Yonezawa, M., Mitsui, K., Tanaka, S., Fujimori, S., Gudis, K., Fukuda, Y., & Sakamoto, C. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0777-z · Cited by 35
“However, COX-2 selective inhibitors have been found to increase the risk of cardiovascular events, curtailing their use as therapeutics for colorectal neoplasms in the clinical setting [5, 35].”
BackgroundWu, L.-C., Leong, P., Yeo, K., Li, T., Wang, Y., Chiou, J., & Wei, J. C. (2016) · Medicine · doi:10.1097/md.0000000000004792 · Cited by 35
Inacio, M. C. S., Cashman, K. S., Pratt, N. L., Gillam, M., Caughey, G. E., Graves, S. E., & Roughead, E. E. (2017) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2017.11.016 · Cited by 39
Divergent roles of prostacyclin and PGE2 in human tendinopathy
Bergqvist, F., Carr, A. J., Wheway, K., Watkins, B., Oppermann, U. C. T., Jakobsson, P., & Dakin, S. G. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1855-5 · Cited by 36
Selecting targets for cancer prevention: where do we go from here?
Szabo, E. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2008 · Cited by 36
Review of clinical trials using early acute intervention with oral triptans for migraine management
Dowson, A. J., Mathew, N. T., & Pascual, J. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00981.x · Cited by 35
Inflammatory Mediators and Nuclear Receptor Signaling in Colorectal Cancer
Wang, D., & DuBois, R. N. (2007) · Cell Cycle · doi:10.4161/cc.6.6.4030 · Cited by 36
“PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways.”
BackgroundInfluentialChressanthis, G. A., Khedkar, P., Jain, N., Poddar, P., & Seiders, M. G. (2012) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00651.x · Cited by 41
“The example of the COX-II inhibitor rofecoxib withdrawal from the market in 2004 comes to mind.(47) Physician-delayed response would have even more validity for a first-in-class drug where no prior actual clinical practice is available to guide physician decisions.”
BackgroundThe Impact of NSAID Treatment on Cardiovascular Risk – Insight from Danish Observational Data
Olsen, A. S., Fosbøl, E. L., & Gislason, G. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12244 · Cited by 42
Cyclooxygenase and prostaglandin synthases: roles in plaque stability and instability in humans
Santovito, D., Mezzetti, A., & Cipollone, F. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832fa22c · Cited by 34
HB-EGF induces cardiomyocyte hypertrophy via an ERK5-MEF2A-COX2 signaling pathway
Lee, K., Park, J., Lim, H., & Park, H. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.01.006 · Cited by 34
Pontes, C., Marsal, J. R., Elorza, J. M., Aragón, M., Prieto‐Alhambra, D., & Morros, R. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.12.011 · Cited by 34
Colchicine: an affordable anti-inflammatory agent for atherosclerosis
Thompson, P. L., & Nidorf, S. M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000552 · Cited by 34
Nishida, Y., Kano, K., Nobuoka, Y., & Seo, T. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa605 · Cited by 35
Update on nonsteriodal anti-inflammatory drugs
Ardoin, S. P., & Sundy, J. S. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000218940.04613.cc · Cited by 34
Lanas, Á., & Ferrández, Á. (2006) · Chinese Journal of Digestive Diseases · doi:10.1111/j.1443-9573.2006.00257.x · Cited by 34
Inflammatory Bowel Disease in the Elderly
Picco, M. F., & Cangemi, J. R. (2009) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.06.006 · Cited by 40
Cardiovascular Events Associated with Long-Term Use of Celecoxib, Rofecoxib and Meloxicam in Taiwan
Huang, W.-F., Hsiao, F., Tsai, Y., Wen, Y., & Shih, Y. (2006) · Drug Safety · doi:10.2165/00002018-200629030-00009 · Cited by 34
Magari, H., Shimizu, Y., Inada, K.-I., Enomoto, S., Tomeki, T., Yanaoka, K., Tamai, H., Arii, K., Nakata, H., Oka, M., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.132 · Cited by 36
Pain Control Following Breast Augmentation: A Qualitative Systematic Review
Stanley, S. S., Hoppe, I. C., & Ciminello, F. S. (2012) · Aesthetic Surgery Journal · doi:10.1177/1090820x12457014 · Cited by 35
Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity
Singh, B. K., Haque, S. E., & Pillai, K. K. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.856881 · Cited by 35
“Finding of this trial indicated that rofecoxib increased CV toxicity risk in patients with a history of colorectal adenomas compared with placebo [4].”
BackgroundPreclinical Evaluation of an Inhibitor of Cytosolic Phospholipase A2α for the Treatment of Asthma
Hewson, C. A., Patel, S., Calzetta, L., Campwala, H., Havard, S., Luscombe, E., Clarke, P. A., Peachell, P. T., Matera, M. G., Cazzola, M., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.186379 · Cited by 35
“It is possible that the reason why orally administered cPLA2 inhibitors have been focused primarily on arthritis and inflammatory pain indications is because of the relative success of COX-2 inhibitors, especially before the Vioxx withdrawal (Bresalier et al., 2005).”
BackgroundRheumatic Diseases and the Cardiovascular System
Villa‐Forte, A., & Mandell, B. F. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00089-5 · Cited by 34
Ushida, T., Matsui, D., Inoue, T., Yokoyama, M., Takatsuna, H., Matsumoto, T., Takita, A., Kurusu, T., Sakoda, H., & Okuizumi, K. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1651840 · Cited by 34
“Although clinical study conducted overseas has shown that rofecoxib, a COX-2-selective inhibitor could increase the risk of serious and fatal cardiovascular disorders such as myocardial infarction and stroke [31], a recent largescale, long-term study in patients with chronic pain (PRECISION trial) showed that the card…”
BackgroundHelicobacter pylori infection and peptic ulcers
Majumdar, D., Bebb, J. R., & Atherton, J. C. (2011) · Medicine · doi:10.1016/j.mpmed.2010.12.003 · Cited by 49
Mackenzie, I. S., Rutherford, D., & MacDonald, T. M. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2464 · Cited by 36
“Recently, NSAIDs (both traditional and cyclo-oxygenase [COX]-2 selective) were linked to an increased incidence of cardiovascular events, at least in patients at increased baseline cardiovascular risk [2-5].”
BackgroundThrombosis and Aging: Fibrin Clot Properties and Oxidative Stress
Konieczyńska, M., Natorska, J., & Undas, A. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0365 · Cited by 40
“Clinical studies have shown that pharmacological inhibition of prostacyclin is associated with a tendency to thrombosis by disrupting the balance between TxA 2 and PGI 2 signaling (Bombardier et al., 2000; Bresalier et al., 2005).”
Concise Review: Human Pluripotent Stem Cell-Based Models for Cardiac and Hepatic Toxicity Assessment
Sartipy, P., & Björquist, P. (2011) · Stem Cells · doi:10.1002/stem.631 · Cited by 35
Liu, D., Liang, J., Wang, Y., & Zheng, L. (2012) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x11202020098 · Cited by 35
Moore, N. D., Gülmez, S. E., Larrey, D. G., Pageaux, G., Lignot, S., Lassalle, R., Jové, J., Pariente, A., Blin, P., Bénichou, J., et al. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3371 · Cited by 33
Rodriguez, G. C., Turbov, J. M., Rosales, R., Yoo, J., HUNN, J., Zappia, K. J., Lund, K., Barry, C. P., Rodriguez, I. V., Pike, J. W., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.022 · Cited by 33
Mitchell, J. A., Shala, F., Elghazouli, Y., Warner, T. D., Gaston‐Massuet, C., Crescente, M., Armstrong, P. C. J., Herschman, H. R., & Kirkby, N. S. (2019) · Circulation Research · doi:10.1161/circresaha.119.314927 · Cited by 33
Tetrandrine Ameliorates Rheumatoid Arthritis in Mice by Alleviating Neutrophil Activities
Lu, Q., Jiang, H., Zhu, Q., Xu, J., Cai, Y., Huo, G., Yuan, K., Huang, G., & Xu, A. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8589121 · Cited by 34
Schmidt, M., Sørensen, H. T., & Pedersen, L. H. (2022) · Drug Safety · doi:10.1007/s40264-022-01211-1 · Cited by 38
“Rofecoxib was withdrawn in 2004 due to the excess thromboembolic risk demonstrated in the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial [17].”
BackgroundTadros, N. N., Bland, L. B., Legg, E., Olyaei, A. J., & Conlin, M. J. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11214.x · Cited by 33
Identifying UMLS concepts from ECG Impressions using KnowledgeMap.
Denny, J. C., Spickard, A., Miller, R. A., Schildcrout, J. S., Darbar, D., Rosenbloom, S. T., & Peterson, J. F. (2005) · Europe PMC (PubMed Central) · Cited by 33
Blouin, M., Han, Y., Burch, J. D., Farand, J., Mellon, C., Gaudreault, M., Wrona, M. D., Lévesque, J.-F., Denis, D., Mathieu, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901771h · Cited by 33
Metadata
- Authors
- Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Mount Sinai Hospital (CA)
- University of Birmingham (GB)
- Tufts Medical Center (US)
- Dartmouth College (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1092-1102
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158131645
- Cited by
- 2,519
- References
- 34
- Citations by year
- 2026: 32 · 2025: 25 · 2024: 17 · 2023: 50 · 2022: 48 · 2021: 37 · 2020: 52 · 2019: 56 · 2018: 63 · 2017: 67 · 2016: 85 · 2015: 107 · 2014: 110 · 2013: 117 · 2012: 120
- FWCI
- 219.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- rofecoxib, cardiovascular adverse events, thrombotic complications, COX-2 inhibitors, colorectal adenoma, colorectal cancer chemoprevention, myocardial infarction, cerebral ischemic events, congestive heart failure, pulmonary edema, cardiovascular mortality
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Lactones, Male, Middle Aged, Risk, Sulfones, Thrombosis, Colorectal Neoplasms, Incidence, Proportional Hazards Models, Single-Blind Method, Cyclooxygenase Inhibitors, Adenomatous Polyps, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.